Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_1
1
33%
Ph phase_2
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting1
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (33.3%)
Phase 11 (33.3%)
Phase 21 (33.3%)

Trials by Status

recruiting133%
active_not_recruiting133%
completed133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruitingearly_phase_1

Fimepinostat in Treating Brain Tumors in Children and Young Adults

NCT03893487
recruitingphase_2

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

NCT05971758
completedphase_1

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

NCT01742988

Clinical Trials (3)

Showing 3 of 3 trials
NCT03893487Early Phase 1

Fimepinostat in Treating Brain Tumors in Children and Young Adults

Active Not Recruiting
NCT05971758Phase 2

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

Recruiting
NCT01742988Phase 1

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3